FDA Approves Gwyn Lo, a Once-Weekly Low-Dose Estrogen Contraceptive Patch

The U.S. Food and Drug Administration has approved Gwyn Lo, a new once-weekly transdermal contraceptive patch, adding a much-needed low-dose estrogen option to the reproductive health landscape. Developed by Viatris Inc., the prescription patch is designed for women of childbearing potential with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for combined hormonal contraception.[2][5]

Gwyn Lo operates on a 28-day cycle, requiring users to apply a new patch once a week for three consecutive weeks, followed by one patch-free week during which a withdrawal bleed typically occurs. The soft, flexible patch can be applied discreetly to clean, dry skin on the upper outer arm, abdomen, buttock, or back.[1]

As a combined hormonal contraceptive (CHC), Gwyn Lo delivers two active ingredients directly through the skin into the bloodstream: a progestin called norelgestromin and an estrogen called ethinyl estradiol. The system provides a controlled, steady delivery of 220 micrograms of norelgestromin and 20 micrograms of ethinyl estradiol per day throughout the seven-day wear interval.[1]

The mechanism of action for Gwyn Lo mirrors that of traditional combination birth control pills. The continuous influx of synthetic hormones primarily works by suppressing the hypothalamic-pituitary-ovarian axis, effectively stopping the ovaries from releasing an egg each month. Without ovulation, there is no egg for sperm to fertilize. Secondary mechanisms include thickening the cervical mucus to inhibit sperm penetration and altering the endometrial lining to reduce the likelihood of implantation.[1]

What sets Gwyn Lo apart from earlier iterations of the contraceptive patch is its dosage. The first contraceptive patch, Ortho Evra, was approved in 2001 but delivered a significantly higher dose of estrogen (35 micrograms per day) and was eventually discontinued. By lowering the ethinyl estradiol dose to 20 micrograms per day, Gwyn Lo aims to provide effective pregnancy prevention while potentially mitigating some of the estrogen-related side effects that have historically deterred patients from transdermal options.[1][5]

The FDA's approval was supported by data from the Phase 3 Luminous Study, a multicenter, open-label, single-arm trial that evaluated the patch's efficacy, safety, and adhesion over a 12-month period. The trial enrolled 1,320 healthy, sexually active women between the ages of 16 and 54.[3][5]

The primary efficacy endpoint of the Luminous Study was the Pearl Index, a standard metric used in clinical trials to measure the effectiveness of birth control methods. The Pearl Index represents the number of pregnancies per 100 woman-years of exposure. Among the efficacy-evaluable population of women aged 18 to 35 years, the Pearl Index for Gwyn Lo was 4.14.[2][5]

This means that approximately four out of 100 women using the patch for a year became pregnant. While this is higher than the failure rates of long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) or implants—which typically see fewer than one pregnancy per 100 women per year—it is comparable to the typical-use failure rates of other user-dependent methods like daily oral contraceptive pills.[1]

A critical factor in the success of any transdermal medication is adhesion—the patch must stay firmly attached to the skin to deliver its medication effectively. The Luminous Study rigorously evaluated this under real-world conditions, including exercise, swimming, and sauna use. Out of nearly 40,000 patches applied during the year-long trial, only 1.3% completely detached, demonstrating robust adhesive performance.[3][5]

The trial also tracked cycle control, a major determinant of patient satisfaction and continuation. Unscheduled bleeding or spotting is a common side effect when starting a new hormonal contraceptive. In the Luminous Study, the incidence of unscheduled bleeding declined significantly over time, dropping from 34.5% in the first cycle to 20.0% by the thirteenth cycle.[2][3]

Importantly, the FDA label for Gwyn Lo includes specific guidance regarding body weight. The patch is indicated only for women with a Body Mass Index (BMI) below 30 kg/m². However, unlike some older contraceptive patches that showed reduced effectiveness in overweight women, the Luminous Study demonstrated that Gwyn Lo maintained its efficacy in women with a BMI between 25 and 29.9 kg/m², with no BMI-based limitation of use within that specific population.[1][5]

The BMI restriction of 30 kg/m² and above is rooted in pharmacokinetics and safety. In women with obesity, the distribution and metabolism of transdermal hormones can be altered, potentially lowering the concentration of the drug in the bloodstream and increasing the risk of contraceptive failure. More critically, obesity is an independent risk factor for venous thromboembolism (VTE), or blood clots.[1][5]

Like all combined hormonal contraceptives, Gwyn Lo carries a Boxed Warning regarding the risk of serious cardiovascular events, particularly for women who smoke. The FDA strictly contraindicates the use of Gwyn Lo in women over 35 years of age who smoke cigarettes, as smoking exponentially increases the risk of heart attack, stroke, and blood clots when combined with estrogen-containing medications.[1][5]

The most common adverse reactions reported during the clinical trials were application-site irritation, redness, and itching. Other side effects included nausea, intercycle bleeding, and heavy withdrawal bleeding. Approximately 7% of participants discontinued the study early due to adverse events, with skin irritation being the most frequent cause.[4]

Gwyn Lo was approved under the FDA's 505(b)(2) regulatory pathway, a provision that allows the agency to rely on data not developed by the applicant—in this case, the extensive historical safety data of the active ingredients norelgestromin and ethinyl estradiol. This pathway accelerates the availability of new delivery systems for established medications.[2][3][5]

The introduction of Gwyn Lo addresses a significant gap in contraceptive care. According to data cited by Viatris, unintended pregnancies accounted for 41.6% of all pregnancies in the United States in 2019. Furthermore, a 2023 CDC survey found that nearly one in five women who used a contraceptive method had changed or stopped it within the previous year, often due to dissatisfaction with the method.[2]

By offering a non-invasive, reversible option that only requires attention once a week, Gwyn Lo provides an alternative for patients who struggle with the daily adherence required by pills, but who may not be ready for or comfortable with the insertion procedures required for IUDs or implants. Viatris expects the patch to be commercially available in pharmacies later in 2026.[2][5]